A Study of Eltrekibart (LY3041658) in Healthy Participants

StatusCompleted
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Primary and study completion dates changed from estimate of Sep 2026 to Sep 22, 2026
  2. Primary and study completion dates: Aug 2026 to Sep 2026
    • Eligibility criteria expanded, about 15 words
  3. Enrollment closed, study ongoing
    • Site details revised
    v3
  4. Recruitment opened
    • Start date changed from estimate of Apr 2026 to Apr 21, 2026
    • Site details revised
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
The main purpose of this study is to evaluate how eltrekibart is absorbed by the body when it is given under the skin to healthy participants. The study will last about 17 weeks.
Trial Details
NCT Number NCT07545590
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Healthy
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov